endo pharmaceuticals

Jefferies is out with its report on Endo Pharmaceuticals (NASDAQ: ENDP), maintaining Buy. In a note to clients, Jefferies writes, "The FDA responded to generic companies' petition in a manner that confirms our call that there is unlikely to ever be generics to old Oxycontin -- a situation which we...

Piper Jaffray has raised the price target on Endo Pharmaceuticals (NASDAQ: ENDP) from $39 to $40 and maintains its Neutral rating.

JP Morgan has published a research report on Endo Pharmaceuticals (NASDAQ: ENDP) after the company received a complete response letter from the FDA regarding Opana ER. In the report, JP Morgan writes "Endo received a complete response (CR) letter from FDA regarding its crush-resistant form of Opana...

On 1/7, Endo Pharmaceuticals Holdings (NASDAQ: ENDP) announced that the FDA issued a complete response letter (CRL) for the tamper resistant formulation of Opana ER, Oppenheimer reports. “We anticipate ENDP will respond to the CRL by mid-2011, with possible approval by 2012, given a six month...

Endo Pharmaceuticals Holdings (NASDAQ: ENDP) announced the FDA approval of Fortesta Gel, the company's topical treatment for low testosterone, Goldman Sachs reports. The company expects to launch the product early in 2011. “Fortesta enters a large and growing market, but we maintain our sales...

J.P. Morgan is out with its research report on Endo Pharmaceuticals (NASDAQ: ENDP) following ENDP's acquisition of Qualitest. In a note to clients, J.P. Morgan writes, "We anticipate Qualitest should contribute $400 million in 2011E revenue to the Endo portfolio, substantially increasing the...

J.P. Morgan resumes coverage on Endo Pharmaceuticals (NASDAQ: ENDP) with an Overweight rating and a $45 price target.

Jefferies & Co. has published a research report on Endo Pharmaceuticals (NASDAQ: ENDP) after the FDA retracted an announcement of a December 2 panel for Opana TR. In the report, Jefferies writes "The entire concept of abuse deterrent opioids has been discussed at numerous panel meetings for...

Citigroup has published a research report on Endo Pharmaceuticals (NASDAQ: ENDP) following 3Q earnings results. In the report, Citigroup writes "Including the nearterm catalyst FDA action dates on Fortesta on 12/30/10 and the long-acting crush resistant oxymorphone on 1/7/10. Endo currently trades...

Citigroup has released its Endo Pharmaceuticals Holdings (NASDAQ: ENDP) core product trends for the week ending 10/15/2010. Lidoderm, Opana, and Frova are among the medications featured in the report. “We arrive at our $40 price target for Endo based on a relative 2011 P/E multiple compared to the...

Stifel Nicolaus reiterates its Buy rating for Apple (NASDAQ: AAPL) and Endo Pharmaceuticals (NASDAQ: ENDP) and has raised the price targets from $350 to $360 and from $30 to $43, respectively.